Commenting on the Spinogenix glaucoma program, and his addition to the Company's SAB, Dr. Weinreb noted, "Glaucoma-related ...

SPG302 is a clinical stage, orally administered small molecule therapeutic with the unique ability to rapidly regenerate glutamatergic synapses. These synapses, a key feature of retinal circuitry ...

Our research supports that GluA4 subunit confers a minimal mechanism for activity-dependent AMPA-receptor regulation to facilitate plasticity during early development of glutamatergic synapses.

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

Recent developments in memristive devices, which emulate biological synapses with reduced power consumption, have shown promise in addressing these issues. This paper explores the use of memristive ...

Synaptic transmission is the biological process by which a neuron communicates with a target cell across a synapse. Chemical synaptic transmission involves the release of a neurotransmitter from ...

Synaptic plasticity is the biological process by which specific patterns of synaptic activity result in changes in synaptic strength and is thought to contribute to learning and memory. Both pre ...

The incidence of depressive illness is high worldwide, and the inadequacy of currently available drug treatments contributes to the significant health burden associated with depression. A basic ...